Partyka A, Golebiowska J, Marciniec K, Canale V, Trybala W, Satala G
Pharmacol Rep. 2025; .
PMID: 40064751
DOI: 10.1007/s43440-025-00713-w.
Shen Y, Hsiao C
Psychiatry Clin Psychopharmacol. 2024; 34(3):272-274.
PMID: 39464693
PMC: 11500432.
DOI: 10.5152/pcp.2024.24865.
Francis B, Ganasan V, Sulaiman A
Medicina (Kaunas). 2024; 60(2).
PMID: 38399570
PMC: 10890360.
DOI: 10.3390/medicina60020283.
Ricci V, de Berardis D, Maina G
Healthcare (Basel). 2024; 12(3).
PMID: 38338224
PMC: 10855531.
DOI: 10.3390/healthcare12030339.
Varadharajan A, Davis A, Ghosh A, Jagtap T, Xavier A, Menon A
J Neurosci Rural Pract. 2023; 14(4):566-573.
PMID: 38059250
PMC: 10696336.
DOI: 10.25259/JNRP_356_2023.
Adjunctive brexpiprazole 1 mg and 2 mg daily for Japanese patients with major depressive disorder following inadequate response to antidepressants: a phase 2/3, randomized, double-blind (BLESS) study.
Kato M, Shiosakai M, Kuwahara K, Iba K, Shimada Y, Saito M
Psychiatry Clin Neurosci. 2023; 78(2):113-122.
PMID: 37933521
PMC: 11488604.
DOI: 10.1111/pcn.13615.
Utility of pharmacogenetic testing to optimise antidepressant pharmacotherapy in youth: a narrative literature review.
Roberts B, Cooper Z, Lu S, Stanley S, Majda B, Collins K
Front Pharmacol. 2023; 14:1267294.
PMID: 37795032
PMC: 10545970.
DOI: 10.3389/fphar.2023.1267294.
The pharmacogenetics of the new-generation antipsychotics - A scoping review focused on patients with severe psychiatric disorders.
Vasiliu O
Front Psychiatry. 2023; 14:1124796.
PMID: 36873203
PMC: 9978195.
DOI: 10.3389/fpsyt.2023.1124796.
Seventy Years of Antipsychotic Development: A Critical Review.
Shad M
Biomedicines. 2023; 11(1).
PMID: 36672638
PMC: 9856208.
DOI: 10.3390/biomedicines11010130.
Antipsychotic drug-aripiprazole against schizophrenia, its therapeutic and metabolic effects associated with gene polymorphisms.
Stelmach A, Guzek K, Roznowska A, Najbar I, Sadakierska-Chudy A
Pharmacol Rep. 2022; 75(1):19-31.
PMID: 36526889
PMC: 9889418.
DOI: 10.1007/s43440-022-00440-6.
The dilemma of polypharmacy in psychosis: is it worth combining partial and full dopamine modulation?.
Lippi M, Fanelli G, Fabbri C, De Ronchi D, Serretti A
Int Clin Psychopharmacol. 2022; 37(6):263-275.
PMID: 35815937
PMC: 9521590.
DOI: 10.1097/YIC.0000000000000417.
Brexpiprazole Reduces 5-HT7 Receptor Function on Astroglial Transmission Systems.
Fukuyama K, Motomura E, Okada M
Int J Mol Sci. 2022; 23(12).
PMID: 35743014
PMC: 9223571.
DOI: 10.3390/ijms23126571.
Newer antipsychotics: Brexpiprazole, cariprazine, and lumateperone: A pledge or another unkept promise?.
Barman R, Majumder P, Doifode T, Kablinger A
World J Psychiatry. 2022; 11(12):1228-1238.
PMID: 35070772
PMC: 8717034.
DOI: 10.5498/wjp.v11.i12.1228.
Brexpiprazole for the Treatment of Schizophrenia and Major Depressive Disorder: A Comprehensive Review of Pharmacological Considerations in Clinical Practice.
Edinoff A, Wu N, Maxey B, Ren A, Leethy K, Girma B
Psychopharmacol Bull. 2021; 51(2):69-95.
PMID: 34092824
PMC: 8146559.
Brexpiprazole caused glycolipid metabolic disorder by inhibiting GLP1/GLP1R signaling in rats.
Li D, Yue Q, Liu L, Che K, Liu X, Hu C
Acta Pharmacol Sin. 2021; 42(8):1267-1279.
PMID: 33976388
PMC: 8285380.
DOI: 10.1038/s41401-021-00680-x.
Modulation of the Serotonergic Receptosome in the Treatment of Anxiety and Depression: A Narrative Review of the Experimental Evidence.
Villas-Boas G, Lavorato S, Paes M, Carvalho P, Rescia V, Cunha M
Pharmaceuticals (Basel). 2021; 14(2).
PMID: 33673205
PMC: 7918669.
DOI: 10.3390/ph14020148.
Dopamine-receptor blocking agent-associated akathisia: a summary of current understanding and proposal for a rational approach to treatment.
Musco S, McAllister V, Caudle I
Ther Adv Psychopharmacol. 2020; 10:2045125320937575.
PMID: 32922732
PMC: 7457694.
DOI: 10.1177/2045125320937575.
The Role of Serotonin in Singultus: A Review.
Petroianu G, Lorke D
Front Neurosci. 2020; 14:629.
PMID: 32765206
PMC: 7378791.
DOI: 10.3389/fnins.2020.00629.
Dopamine Receptor Partial Agonists for the Treatment of Bipolar Disorder.
Azorin J, Simon N
Drugs. 2019; 79(15):1657-1677.
PMID: 31468317
DOI: 10.1007/s40265-019-01189-8.
Brexpiprazole, a Serotonin-Dopamine Activity Modulator, Can Sensitize Glioma Stem Cells to Osimertinib, a Third-Generation EGFR-TKI, via Survivin Reduction.
Suzuki S, Yamamoto M, Sanomachi T, Togashi K, Sugai A, Seino S
Cancers (Basel). 2019; 11(7).
PMID: 31284441
PMC: 6679129.
DOI: 10.3390/cancers11070947.
